Table 1.
Demographic and clinical characteristics from study cohort.
| Control Group |
SLE Group |
||
|---|---|---|---|
| Healthy Controls (n = 22) | AID Controls (n = 121) | SLE (n = 192) | |
| Sex: female, n (%)a | 18 (81.8 %) | 90 (74.3 %) | 173 (90.1 %) |
| Age, mean ± SD (years)b | 35.1 ± 11.8 | 57.9 ± 15.4 | 47 ± 13.8 |
| Age at diagnosis, mean ± SD (years) | – | – | 32.8 ± 13.8 |
| Disease duration, mean ± SD (years) | – | – | 15.2 ± 10.3 |
| Treatment, n (%) | – | – | 172 (89.5 %) |
| Hypocomplementemia, n (%) | – | – | 66 (34.3 %) |
Active disease:
|
– | – | 22 (11.4 %) 19 (9.8 %) |
| Major organ involvement (at sampling), n (%) | – | – | 33 (17.1 %) |
| Mucocutaneous involvement, n (%) | – | – | 16 (8.3 %) |
| Musculoskeletal involvement, n (%) | – | – | 12 (6.2 %) |
| Renal involvement, n (%) | – | – | 6 (3.1 %) |
| Haematological involvement, n (%) | – | – | 5 (2.6 %) |
| Neurological involvement, n (%) | – | – | 0 |
| Serosal involvement, n (%) | – | – | 0 |
a
p = 0.001 Control group vs SLE group.
b
p < 0.001 Control group vs SLE group.